Item | Enrolled (N = 104) |
---|---|
Age (years) mean (SD) | 65.1 (10.3) |
Race n (%) | |
White | 67 (64.4%) |
Black | 1 (1.0%) |
Hispanic | 36 (34.6%) |
Living Situation | |
Living alone | 25 (24.0%) |
Living with another | 77 (74.0%) |
Other | 2 (1.9%) |
Work Status | |
Full-time | 17 (16.3%) |
Part-time | 19 (18.3%) |
Currently not working at a paid job | 61 (58.7%) |
Other | 7 (6.7%) |
Education (highest level completed) | |
Elementary | 4 (3.8%) |
High school | 38 (36.5%) |
Some college | 31 (29.8%) |
College degree | 19 (18.3%) |
Postgraduate | 10 (9.6%) |
Other | 2 (1.9%) |
Time since diagnosis (years), mean ± SD | 6.4 ± 7.0 |
No Health Insurance | 16 (15.4%) |
Time since first starting prescription meds for osteoporosis (bisphosphonates) | |
< 3 months ago | 7 (6.7%) |
> 3 months – 1 year | 14 (13.5%) |
> 1 – 3 years ago | 35 (33.7%) |
> 3 years | 48 (46.2%) |
Current Osteoporosis Treatment 1 | |
Weekly alendronate | 61 (59%) |
Daily alendronate | 13 (13%) |
Weekly risendronate | 21 (20%) |
Daily risendronate | 6 (6%) |
Experienced at least 1 fracture since menopause n (%) | 27 (26.0%) |
Comorbid conditions n (%) | |
Angina | 3 (2.9%) |
Arthritis | 59 (56.7%) |
COPD | 6 (5.8%) |
Congestive heart failure | 3 (2.9%) |
Depression | 17 (16.3%) |
Hypertension | 32 (30.8%) |
Other | 26 (25.0%) |